A Prospective, Multicenter, Single-arm, Open-label, Phase 4 Study to Evaluate the Effects of Macitentan on Right vEntricular Remodeling in Pulmonary ArterIal hypeRtension Assessed by Cardiac Magnetic Resonance Imaging
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Macitentan (Primary) ; Type 5 cyclic nucleotide phosphodiesterase inhibitors
- Indications Pulmonary arterial hypertension
- Focus Therapeutic Use
- Acronyms REPAIR
- Sponsors Actelion Pharmaceuticals
- 17 May 2021 Results of an analysis assessing the compare standardized treatment effect sizes (STES) of cMRI, hemodynamic and functional endpoints presented at the 70th Annual Scientific Session of the American College of Cardiology
- 21 Oct 2020 Results from REPAIR ECHO substudy presented at the CHEST Annual Meeting 2020 by Annual Meeting of the American College of Chest Physicians
- 24 Sep 2020 Results published in the ClinicalTrials.gov Trial Registry